Fatty acid synthase (FAS), a key enzyme of the fatty acid biosynthetic pathway, has been shown to be overexpressed in various types of human cancer and is, therefore, considered to be an attractive target for anticancer therapy. However, the exact mechanism of overexpression of the FAS gene in tumor cells is not well understood. In this report, we demonstrate that the expression of the tumor suppressor gene PTEN has a significant inverse correlation with FAS expression in the case of prostate cancer in the clinical setting, and inhibition of the PTEN gene leads to the overexpression of FAS in vitro. We also found that the combination of the expression status of these two genes is a better prognostic marker than either gene alone. Furthermore, our results indicate that the specific inhibition of FAS gene by siRNA leads to apoptosis of prostate tumor cells, and inhibition of PI 3-kinase pathway synergizes with FAS siRNA to enhance tumor cell death. These results provide a strong rationale for exploring the therapeutic use of an inhibitor of the PTEN signaling pathway in conjunction with the FAS siRNA to inhibit prostate tumor growth.
Fatty acid is an essential factor for diverse cellular functions including energy storage, membrane formation, signal transduction and protein acylation (Kuhajda, 2000) . Animals derive fatty acids from diet as well as de novo synthesis, which is catalysed by the enzyme fatty acid synthase (FAS) . FAS is a 250-270 kDa cytosolic protein that forms a homodimer and catalyses the synthesis of palmitate from the condensation of malonyl CoA and acetyl CoA. This enzyme also plays an important role in energy homeostasis by converting excess carbon intake into fatty acids for storage, which, when necessary, provide energy via b-oxidation (Kuhajda, 2000) . Since diet supplies most of the fatty acids, the endogenous synthesis of fatty acid is usually minimal in cells. Consequently, FAS is expressed at low or undetectable level in most normal human tissues, with the exception of lactating breast and cycling endometrium (Kuhajda, 2000) . In contrast, FAS is overexpressed in a variety of human malignancies including the prostate, breast, ovarian, endometrial, lung, colorectal, stomach and skin cancer (Epstein et al., 1995; Alo' et al., 1996; Shurbaji et al., 1996; Gansler et al., 1997; Milgraum et al., 1997; Rashid et al., 1997; Piyathilake et al., 2000; Kusakabe et al., 2002; Swinnen et al., 2002; Innocenzi et al., 2003; Sebastiani et al., 2004) . In these cancer cells, FAS expression is found to be elevated despite the high level of ambient fatty acids and is, seemingly, independent of the regulatory signals that downregulate fatty acid synthesis in normal cells. Although the exact role of the FAS gene in tumorigenesis is yet to be elucidated, treatment of tumor cells with pharmacological inhibitors of FAS leads to cell cycle arrest and apoptosis (Kuhajda, 2000) . These observations suggest that FAS overexpression confers a selective advantage to tumor cells by inhibiting apoptosis and promoting cell cycle progression. As FAS is downregulated in most normal human tissues and is overexpressed in a variety of tumors, FAS is considered to be an attractive target for anticancer therapy. However, relatively little is known about the regulatory mechanisms controlling FAS gene expression in human tumors, and understanding these mechanisms is of paramount interest to design intervention of the FAS enzymatic pathway.
Thus far, several factors including androgen, epidermal growth factor (EGF), PTEN and p53 have been demonstrated to modulate the expression of the FAS gene in vitro. Recent functional analyses of the promoter of the FAS gene suggest that sterol regulatory element binding proteins (SREBP) and insulin play major role in the regulation of FAS gene expression (Magana and Osborne, 1996; Sul et al., 2000) . Indeed, androgen and EGF have been found to elevate the expression of the FAS gene in prostate cancer cells in vitro through the action of the SREBPs (Swinnen et al., 2000; Heemers et al., 2001) . FAS has also been shown to be regulated by the tumor suppressor gene PTEN in vitro ( Van de Sande et al., 2002) . This regulation is thought to be mediated by a PI 3-kinase/Akt-dependent pathway, since overexpression of Akt-1 enhanced the expression of the FAS gene, while treatment of the cells with a PI 3-kinase inhibitor reduced FAS expression (Van de Sande et al., 2002; Yang et al., 2002) . Another tumor suppressor gene p53 has also been suggested to be involved in the regulation of FAS in a colon carcinoma cell line in vitro (Li et al., 2001) . Thus, the FAS gene appears to be regulated by multitude of factors in malignant cells at least in culture. However, to develop a viable therapeutic intervention of the FAS activity via any of these pathways, it is essential to validate the involvement of these factors at the clinical setting.
In order to examine the relationship between different clinicopathological factors and FAS expression levels in prostate cancer, an immunohistochemical analysis was performed on 78 prostate tumor specimens, randomly selected from surgical pathology archives of the Akita Red Cross Hospital (Akita, Japan), dating from 1988 to 2001. The prostate cancer specimens included 34 cases of needle biopsy, 12 cases of transurethral resection and 32 cases of radical prostatectomy. The ages of the patients ranged from 53 to 89 years, with a mean of 72 years. Each patient sample was assigned two separate Gleason grades, corresponding to the two predominant histological patterns. The nuclear grades were determined according to the WHO criteria, and the degree of differentiation was classified into 'well', 'moderate' or 'poor' by pathologists. Complete 5-year follow-up data were available for 43 patients, and those who died of other causes were eliminated from the study. As shown in Figure 1a , FAS expression was found to be highly elevated in prostatic tumor cells compared to the expression level in the epithelial cells of normal ducts and glands. Less than 10% of the cells in benign prostatic hyperplasia expressed FAS, while the stroma, endothelial cells and nerve bundles did not frequently (o5%) express the FAS gene. In the cancerous cells, FAS expression was mostly cytoplasmic and nuclear stain was observed in only o1% of the cells. Notably, expression of the FAS gene exhibited a significant correlation with the degree of differentiation as well as Gleason grade, which is also consistent with previous observations (Epstein et al., 1995; Shurbaji et al., 1996; Swinnen et al., 2002) . However, the degree of metastasis had no significant correlation with FAS expression, which suggests that overexpression of the FAS gene is a relatively early event in human prostate cancer. We then examined the relationship of FAS expression with several potential regulatory factors, including androgen, EGF, PTEN and p53 by analysing the same set of prostate cancer specimens. We found that, among these factors, PTEN was expressed at a high level in normal prostatic glands and ducts, while the poorly differentiated tumor cells in the same specimen had significantly reduced level of PTEN expression (Figure 1a ). In fact, as shown in a representative field in Figure 1a, Figure 1b) . Therefore, expression of the FAS gene, for the most part, appears to be independent of these factors in human prostate cancer, although the possibility of involvement of some downstream pathways regulated by these factors cannot be ruled out.
Since the result of IHC analysis indicated that the loss of PTEN significantly correlated with the overexpression of FAS in prostate cancer, we examined whether abrogation of the PTEN expression indeed elevated the expression of the FAS gene in tumor cells. To knock down the PTEN expression, four individual siRNAs directed against the PTEN gene were pooled and transfected into PTEN-positive prostate cancer cell line, DU-145. As shown in Figure 1c , we found that abrogation of PTEN expression by 100, 200 and 300 nM siRNA was followed by a significant increase in the expression of the FAS gene, while the PTEN expression was notably suppressed. This effect was mediated specifically by PTEN siRNA, since equivalent amount of GFP siRNA did not affect the expression of PTEN or FAS gene ( Figure 1c , right panels). We observed similar effect of PTEN inhibition on the expression of the FAS gene in the PTEN-positive breast carcinoma cell lines, MDA-435 and MCF-7 (Supplementary Figure 1 ). As a complementary approach, we overexpressed the PTEN gene in PTEN-negative prostate carcinoma cells, PC3 and ALVA, and found that PTEN downregulated the expression of the FAS gene in a dose-dependent manner in these cells (Figure 1d ). These results corroborate the notion that PTEN controls the expression of the FAS gene, and suggests that the loss of PTEN expression, which is frequently observed in the case of human prostate cancer, leads to the upregulation of FAS expression.
To further clarify the roles of PTEN and FAS gene expression in prostate cancer, we next evaluated the prognostic importance of the combination of these two markers. Univariate survival analysis was performed using the Kaplan-Meier method in the prostate cancer cases with a 5-year follow-up. As shown in Figure 2a , patients with negative expression of PTEN and elevated expression of FAS (PTEN À FAS þ ) had significantly worse (P ¼ 0.0047) overall survival rate than the other three patient groups (
. Importantly, Cox regression analysis (Figure 2b ) revealed that the combination of PTEN and FAS gene expression was an independent prognostic marker for prostate cancer. The hazard ratio of FAS (positive expression) and PTEN (negative expression) as individual marker was 4.454 and 2.819, respectively. When both markers were combined, however, the hazard ratio was 11.525, meaning that the death risk of a patient with positive expression of FAS and negative PTEN expression (PTEN À FAS þ ) was 11.525 It has been suggested that the upregulation of FAS observed in various tumor cells is due to the selective advantage that the FAS gene confers by promoting proliferation and inhibiting apoptosis in these cells. Therefore, the specific inhibition of FAS gene is expected to result in the blockade of tumor cell growth. To examine the effect of direct inhibition of the expression of the FAS gene in prostate cancer cells, four individual siRNAs against the FAS gene, in combination, were transfected into the FAS-positive prostate cancer cell lines, ALVA, PC3 and DU-145. As shown in Figure 3a , 300 nM of the siRNA abrogated the expression of the FAS gene in a time-dependent manner in all the cell lines tested, with a significant effect being observed 48 h post-transfection. Furthermore, when various amounts of the FAS siRNA were transfected into these cells, the siRNA dose dependently inhibited the expression of the FAS gene, indicating the efficacy of this set of siRNA in knocking down FAS expression (Figure 3b) . In order to examine the effect of the direct inhibition of the FAS gene, the prostate cancer cells were transfected with various amounts of FAS siRNA or equivalent amounts of GFP siRNA, and the extent of apoptosis was measured by assessing the DNA fragmentation. As shown in Figure 3c , in each case, FAS siRNA significantly augmented the degree of apoptosis in both dose-and time-dependent manner. This effect was mediated specifically by the inhibition of the FAS gene, since equivalent amounts of GFP siRNA did not have any such effect (Figure 3c ). These results suggest that this set of siRNAs, specifically targeted to the FAS gene, leads to apoptosis of tumor cells and, therefore, is potentially useful for therapeutic application.
As described above, our data suggest that PTEN controls the expression of the FAS gene both in vitro and in vivo. PTEN is a dual specificity phosphatase that inhibits PI 3-kinase-dependent activation of Akt, and deletion or inactivation of PTEN results in constitutive Akt activation (Cantley and Neel, 1999) . Notably, Akt has also been shown to modulate the expression of the FAS siRNA (nM) ---50  50  50  100 100  100  PTEN  -+  --+  --+  -LY29  --+  --+  - Yang et al., 2002) . Therefore, to explore the possibility that inhibition of PI 3-kinase/Akt pathway could cooperate with the gene-specific siRNA to block the expression of the FAS gene, we treated the prostate cancer cells with the FAS siRNA and PTEN expression vector or PI 3-kinase inhibitor, Ly294002. As shown in Figure 4A , in prostate cancer cell lines, ALVA, PC3 and DU-145, low amount of PTEN expression plasmid, 100 nM LY294002 or 50 nM FAS siRNA individually did not have any significant effect on the expression of the FAS gene. The same dose of PTEN expression vector or LY294002, however, cooperated with different doses of FAS siRNA and significantly abrogated the FAS expression. This result is consistent with the notion that PTEN downregulates the expression of the FAS gene and raises an attractive possibility to inhibit FAS in prostate tumor cells using a combination of FAS siRNA and an inhibitor of PI 3-kinase/Akt pathway. To further explore this possibility, we treated the prostate cancer cells with 100 nM Ly294002, various doses of FAS siRNA or a combination of both, and examined the apoptotic index. As shown in Figure 4C (a), in the case of prostate cancer cell line, ALVA, while 100 nM Ly294002 or 50 nM FAS siRNA alone induced apoptosis in only 10.2 and 19.4% of cells, respectively, the extent of apoptosis was strikingly higher (45.9%) when a combination of both the agents was used. Thus, the apoptotic effect of the combination of PI 3-kinase inhibitor and FAS siRNA significantly exceeded the sum of either agent administered alone, indicating a significant synergistic interaction between these two agents (P ¼ 0.006). It should be noted that such synergistic effect was caused specifically by the FAS siRNA, since 50 nM GFP siRNA alone or in combination with 100 nM Ly294002, induced apoptosis in o1 and 11.3% cells, respectively. Similarly, in PC3 cells, 100 nM Ly294002, 50 nM FAS siRNA or 50 nM GFP siRNA caused apoptosis in 20.4, 14 and o1% cells, respectively, while the combination of Ly294002 and FAS siRNA or Ly294002 and GFP siRNA induced apoptosis in 58.8 and 20% cells, indicating a specific and significant (P ¼ 0.004) synergy between Ly294002 and FAS siRNA ( Figure 4C (b) ). In the case of DU-145, 100 nM Ly294002, 50 nM FAS siRNA or 50 nM GFP siRNA caused apoptosis in 16.8, 11.3 and o1% cells, respectively. However, the combination of Ly294002 and FAS siRNA or Ly294002 and GFP siRNA induced apoptosis in 29 and 15% cells, indicating an additive but not synergistic effect of the combination of Ly294002 and FAS siRNA ( Figure 4C (c) ). The lack of synergistic interaction between these two agents in DU-145 may be at least partially explained by the high endogenous level of PTEN in these cells. These results provide a strong rationale for exploring the therapeutic use of an inhibitor of the PI 3-kinase pathway in conjunction with the FAS siRNA, particularly in patients lacking the PTEN activity, which is a common occurrence in human prostate cancer. PTEN signaling pathway is strongly implicated in the development of prostate cancer. It has been demonstrated that mice with prostate-specific biallelic deletion of the PTEN gene spontaneously develop PIN (prostatic intraepithelial neoplasia) lesions followed by invasive adenocarcinoma, and more than 50% of the animals develop pulmonary metastasis by 29 weeks of age (Wang et al., 2003) . PTEN deletions are found in 30% of primary prostate cancers and 63% of metastatic prostate tissue samples, placing PTEN mutation among the most common genetic alterations in human prostate cancer (Suzuki et al., 1998; Dahia, 2000) . On the other hand, FAS, which plays a central role in de novo lipogenesis, is known to be overexpressed in various types of tumors including prostate cancer. These observations raised a possibility of a functional relationship between these two genes; however, the expression of FAS and PTEN genes has not been previously examined in a comparative manner in clinical samples of cancer patients. In this report, we have demonstrated that the expression of the PTEN gene has a significant inverse correlation with FAS expression level in the case of prostate cancer. Furthermore, mimicking the situation of loss of PTEN expression in human prostate cancer, we knocked down the expression of the PTEN gene, which led to the upregulation of the FAS expression. These results strongly implicate that loss of the PTEN gene leads to elevation of FAS expression in human prostate cancer. We have also demonstrated that combination of PTEN and FAS expression can be an independent prognostic factor in the case of human prostate cancer, which also indicates the significance of the PTEN-FAS regulatory pathway at the clinical setting.
FAS, which is selectively overexpressed in the cancer cells, is an attractive target for anticancer therapy. The pharmacological inhibitors of FAS such as cerulenin, C75 and Orlistat have been shown to significantly suppress the cellular FAS level and also induce apoptosis in a variety of human cancer cells including the prostate, breast and ovarian cancer (Pizer et al., 1996 Pflug et al., 2003; Kridel et al., 2004) . However, the specificity of action of these inhibitors is a major concern, as they are also known to inhibit protein palmitoylation, protein acylation and cholesterol synthesis, and to cause undesirable side effects such as anorexia and weight loss (Malvoisin and Wild, 1990; Jochen et al., 1995; Clegg et al., 2002; Takahashi et al., 2004) . It is therefore desirable to develop a strategy that will specifically inhibit the expression of the FAS gene.
In this report, we demonstrated the efficacy of a set of FAS siRNA to abrogate directly the expression of the FAS gene and trigger apoptosis, which is also consistent with a recent report, where FAS siRNA has been shown to cause apoptosis in LnCaP cells in vitro (De Schrijver et al., 2003) . While siRNA is a powerful tool to downregulate a particular gene, there are also several limitations for its practical usage such as problems with stability and delivery (Woessmann et al., 2003) . Therefore, combinatorial approach with highly effective multiple agents are warranted. Based on our clinical observations and in vitro data that PTEN inhibits the expression of the FAS gene, we explored the possibility of inhibiting the PTEN signaling pathway and FAS in conjunction, and found that the FAS siRNA indeed synergized with the PI 3-kinase inhibitor to trigger apoptosis in prostate cancer cells. Together, the data presented in this paper define PTEN as a regulatory factor for FAS expression in vivo and provide a strong rationale for use of the inhibitor of PTEN signaling pathway with direct inhibition of the FAS gene as an anticancer therapeutic approach.
